| INTRODUCTION
Akathisia is a neuropsychiatric syndrome characterized by a subjective inner feeling of restlessness and a compulsion to move accompanied by repetitive movement of the legs that can also affect the trunk and arms. 1 In clinical settings akathisia occurs as an adverse effect of medications. The Diagnostic and Statistical Manual for Mental Disorders fifth edition defines medication-induced akathisia as a subjective complaint of restlessness, often accompanied by excessive movements, developed within a few weeks of starting or raising the dosage of a medication or after reducing the dosage of a medication used to treat extrapyramidal symptoms. 2 While several drugs can cause akathisia, antipsychotics are most commonly associated with this adverse effect. 1 These drugs are thought to block D2/D3 receptors at the ventral striatum in the central nervous system causing akathisia. 3 Highpotency, first-generation antipsychotics have a higher prevalence of akathisia, compared with low-to intermediate-potency first-and second-generation atypical antipsychotics. Second-generation antipsychotics differ in terms of their propensity for akathisia as well, with higher rates reported for aripiprazole and lurasidone compared with iloperidone, quetiapine, and clozapine.
The prevalence, phenomenology, and management of antipsychotic-induced akathisia in delirium and palliative care settings have not been vigorously studied. In a recent systematic review, a total of 10 studies that reported incidence of antipsychotic-induced akathisia in delirium settings were found. Neither of these studies used objective scales for the assessment of akathisia. Among those studies, the prevalence of akathisia varied from 0% to 28.5%, depending on the antipsychotic used and the dose of antipsychotic. A higher incidence was found in patients taking haloperidol and ziprasidone. 4 In a study published in 2013, Crawford and colleagues found an incidence of akathisia of 11% in hospice and palliative care settings at a dose of 2.1 mg of haloperidol daily. The authors concluded that patients with terminal illnesses may be at higher risk for development of this extrapyramidal adverse effect. 5 A Japanese study found a prevalence of akathisia of 4.8% in 483 patients with cancer who met criteria for different psychiatric diagnoses. 6 Assessing for akathisia in patients with cancer can be challenging. For instance, in these settings, patients can often develop delirium because of dehydration, malnutrition, metabolic abnormalities, and opioid use among other causes. Delirium often presents with cognitive impairment, anxiety, and agitation. These symptoms overlap with akathisia symptoms. 7 Moreover, patients with a history of anemia and restless legs syndrome, Parkinson's disease, or other neurodegenerative diseases affecting the basal ganglia may be more sensitive to development of antipsychotic-induced akathisia.
The aim of this study is firstly to determine the prevalence of antipsychotic-induced akathisia in patients with cancer and comorbid psychiatric conditions by using an objective scale and secondly to explore whether there are differences in rates of akathisia depending on the antipsychotic used, the dose of the antipsychotic, and the indication for which the antipsychotic was used. The small number of patients who met criteria for antipsychoticinduced akathisia (n = 2) did not allow for any group comparisons. As a result the 2 cases are discussed below in a case series format ( 
| Case 2
A 55-year-old man with a history of acute myeloid leukemia, 60 days following bone marrow transplant, was admitted for treatment of graft-versus-host disease affecting his liver and gastrointestinal system. He had no past psychiatric history. He developed acute kidney failure after treatment with tacrolimus. Patient became confused, became disoriented, and reported hallucinations of "circles" and "things."
On evaluation by the psychiatry team, he showed impairments in attention, registration, working memory, and executive functioning. He was treated with intravenous haloperidol 0.5 mg twice daily for delirium of mixed subtype. A day after initiation of haloperidol, he developed akathisia symptoms. His BARS scores were 2 for subjective awareness, 3 for subjective distress, 3 for objective akathisia, and 5 for global subscales, which is consistent with severe akathisia.
Haloperidol was switched to 0.5 mg twice daily as needed only. Two days later, he continued to report subjective inner feelings of restlessness and distress but showed no objective signs of akathisia.
The patient was not given any haloperidol for the following week.
A week later, he was started on quetiapine 25 mg every night by mouth for treatment of symptoms of delirium. The day after, his BARS scores were 2 for subjective awareness, 2 for subjective dis- Total prevalence in our sample was low, 5.1%, when compared with other studies, with up to 28.5% akathisia prevalence. 9 This difference could be due to the facts that we used low doses of antipsychotic medications and that we increased the specificity of akathisia diagnosis by using an objective measurement, namely, BARS. The fact that akathisia symptoms started after the commencement of the offending agent (ie, haloperidol) and attenuated with the decrease or discontinuation of it supports the diagnosis of antipsychoticinduced akathisia in our sample. 
